192 related articles for article (PubMed ID: 21656902)
1. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Yoon HS; Park TS; Jeong KH
Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
[No Abstract] [Full Text] [Related]
2. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
3. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
5. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Tallman MS; Manji GA
Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
[No Abstract] [Full Text] [Related]
6. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
Yamamoto Y; Sasaki M; Oshimi K; Sugimoto K
Acta Haematol; 2009; 122(1):52-3. PubMed ID: 19816009
[No Abstract] [Full Text] [Related]
7. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
9. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
10. Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
Au WY; Chim CS; Wai Lie AK; Pang A; Kwong YL
Haematologica; 2002 Oct; 87(10):1109-11. PubMed ID: 12368167
[No Abstract] [Full Text] [Related]
11. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
[TBL] [Abstract][Full Text] [Related]
13. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
[No Abstract] [Full Text] [Related]
14. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Inoue A; Kawakami C; Takitani K; Tamai H
Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
[No Abstract] [Full Text] [Related]
15. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
16. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
[No Abstract] [Full Text] [Related]
17. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Park JH; Tallman MS
Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
[TBL] [Abstract][Full Text] [Related]
18. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
19. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
[No Abstract] [Full Text] [Related]
20. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
